Your browser doesn't support javascript.
loading
mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021.
McLean, Huong Q; McClure, David L; King, Jennifer P; Meece, Jennifer K; Pattinson, David; Neumann, Gabriele; Kawaoka, Yoshihiro; Rolfes, Melissa A; Belongia, Edward A.
Afiliación
  • McLean HQ; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • McClure DL; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • King JP; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • Meece JK; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • Pattinson D; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Neumann G; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Kawaoka Y; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA.
  • Rolfes MA; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Belongia EA; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Influenza Other Respir Viruses ; 16(4): 607-612, 2022 07.
Article en En | MEDLINE | ID: mdl-35178857
Reduced COVID-19 vaccine effectiveness (VE) has been observed with increasing predominance of SARS-CoV-2 Delta (B.1.617.2) variant. Two-dose VE against laboratory-confirmed SARS-CoV-2 infection (symptomatic and asymptomatic) was estimated using Cox proportional hazards models with time-varying vaccination status in a prospective rural community cohort of 1266 participants aged ≥12 years. Between November 3, 2020 and December 7, 2021, VE was 56% for mRNA COVID-19 vaccines overall, 65% for Moderna, and 50% for Pfizer-BioNTech. VE when Delta predominated (June to December 2021) was 54% for mRNA COVID-19 vaccines overall, 59% for Moderna, and 52% for Pfizer-BioNTech.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos